CA2250232A1 — A method of treating cancer
Assigned to Merck and Co Inc · Expires 1997-10-09 · 29y expired
What this patent protects
The present invention relates to a method of treating cancer which comprises administering to a mammalian patient a compound which inhibits Raf and a compound which inhibits farnesyl protein transferase.
USPTO Abstract
The present invention relates to a method of treating cancer which comprises administering to a mammalian patient a compound which inhibits Raf and a compound which inhibits farnesyl protein transferase.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.